A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma von Chng, Wee-Joo, Lonial, Sagar, Morgan, Gareth J., Iida, Shinsuke, Moreau, Philippe, Kumar, Shaji K., Twumasi-Ankrah, Philip, Villarreal, Miguel, Dash, Ajeeta B., Vorog, Alexander, Zhang, Xiaoquan, Suryanarayan, Kaveri, Labotka, Richard, Dimopoulos, Meletios A., Rajkumar, S. Vincent

Volltext

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML von Swords, Ronan T., Coutre, Steven, Maris, Michael B., Zeidner, Joshua F., Foran, James M., Cruz, Jose, Erba, Harry P., Berdeja, Jesus G., Tam, Wayne, Vardhanabhuti, Saran, Pawlikowska-Dobler, Iwona, Faessel, Hélène M., Dash, Ajeeta B., Sedarati, Farhad, Dezube, Bruce J., Faller, Douglas V., Savona, Michael R.

Volltext

Mesenchymal stem cells within tumour stroma promote breast cancer metastasis von KARNOUB, Antoine E, DASH, Ajeeta B, VO, Annie P, SULLIVAN, Andrew, BROOKS, Mary W, BELL, George W, RICHARDSON, Andrea L, POLYAK, Kornelia, TUBO, Ross, WEINBERG, Robert A

Volltext

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials von Paiva, Bruno, Manrique, Irene, Dimopoulos, Meletios A., Gay, Francesca, Min, Chang-Ki, Zweegman, Sonja, Špička, Ivan, Teipel, Raphael, Mateos, María-Victoria, Giuliani, Nicola, Cavo, Michele, Hopkins, Christine Rojas, Fu, Weijun, Suryanarayan, Kaveri, Vorog, Alexander, Li, Cong, Wang, Bingxia, Estevam, Jose, Labotka, Richard, Dash, Ajeeta B.

Volltext

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumo... von Lockhart, A Craig, Bauer, Todd M., Aggarwal, Charu, Lee, Carrie B., Harvey, R Donald, Cohen, Roger B., Sedarati, Farhad, Nip, Tsz Keung, Faessel, Hélène, Dash, Ajeeta B., Dezube, Bruce J., Faller, Douglas V., Dowlati, Afshin

Volltext

A Murine Model of CML Blast Crisis Induced by Cooperation between BCR/ABL and NUP98/HOXA9 von Dash, Ajeeta B., Williams, Ifor R., Kutok, Jeffery L., Tomasson, Michael H., Anastasiadou, Ema, Lindahl, Kathleen, Li, Shaoguang, Van Etten, Richard A., Borrow, Julian, Housman, David, Druker, Brian, Gilliland, D. Gary

Volltext

Pim-1 Kinase and p100 Cooperate to Enhance c-Myb Activity von Leverson, Joel D, Koskinen, Päivi J, Orrico, Frank C, Rainio, Eeva-Marja, Jalkanen, Katriina J, Dash, Ajeeta B, Eisenman, Robert N, Ness, Scott A

Volltext

Clinical benefit of ixazomib plus lenalidomide‐dexamethasone in myeloma patients with non‐canonical NF‐κB pathway activation von Dash, Ajeeta B., Zhang, Jacob, Shen, Lei, Li, Bin, Berg, Deborah, Lin, Jianchang, Avet‐Loiseau, Hervé, Bahlis, Nizar J., Moreau, Philippe, Richardson, Paul G., Di Bacco, Alessandra

Volltext

Preclinical evaluation of the CD38‐targeting engineered toxin body MT‐0169 against multiple myeloma von Bruins, Wassilis S. C., Rentenaar, Rosa, Newcomb, John, Zheng, Wenrou, Ruiter, Ruud W. J., Baardemans, Thomas, Poma, Eric, Moore, Chris, Robinson, Garrett L., Lublinsky, Anya, Zhang, Yuhong, Syed, Sakeena, Milhollen, Michael, Dash, Ajeeta B., Donk, Niels W. C. J., Groen, Richard W. J., Zweegman, Sonja, Mutis, Tuna

Volltext

DNA Methylation Analysis before and during Treatment with Azacitidine Plus Pevonedistat or Azacitidine Alone in Patients with MDS, CMML, and AML Previously Untreated with Hypomethy... von Park, Soo, Reilly, Brian M, Luger, Timothy, Zhao, Dan, Fram, Robert J., Dash, Ajeeta B, Bejar, Rafael

Volltext

TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells von Bruins, Wassilis S.C., Zheng, Wenrou, Higgins, Jack P., Willert, Erin K., Newcomb, John, Dash, Ajeeta B, Van De Donk, Niels W.C.J., Zweegman, Sonja, Mutis, Tuna

Volltext

Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placeb... von Chng, Wee-Joo, Lonial, Sagar, Morgan, Gareth J., Iida, Shinsuke, Moreau, Philippe, Kumar, Shaji, Twumasi-Ankrah, Philip, Kumar, Arun, Dash, Ajeeta B., Vorog, Alexander, Zhang, Xiaoquan, Suryanarayan, Kaveri, Labotka, Richard, Dimopoulos, Meletios A., Rajkumar, S. Vincent

Volltext

Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD+ Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Ma... von Paiva, Bruno, Manrique, Irene, Giuliani, Nicola, Cavo, Michele, Rojas, Christine, Fu, Weijun, Mateos, María-Victoria, Dimopoulos, Meletios A, Vorog, Alexander, Li, Cong, Wang, Bingxia, Labotka, Richard J, Dash, Ajeeta B

Volltext

Comparing Bortezomib-Lenalidomide-Dexamethasone (VRd) with Carfilzomib-Lenalidomide-Dexamethasone (KRd) in the Patients with Newly Diagnosed Multiple Myeloma (NDMM) in Two Observat... von Li, Bin, Ren, Kaili, Shen, Lei, Hou, Peijie, Su, Zhenqiang, Di Bacco, Alessandra, Hong, Jin-Liern, Galaznik, Aaron, Dash, Ajeeta B, Crossland, Victoria, Dolin, Paul, Szalma, Sandor

Volltext

Addition of Ixazomib to an Rd Backbone Improves Clinical Benefit in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Non-Canonical NF-KB Activation — Results from th... von Dash, Ajeeta B, Zhang, Jacob, Shen, Lei, Li, Bin, Berg, Deborah, Lin, Jianchang, Avet-Loiseau, Hervé, Bahlis, Nizar, Moreau, Philippe, Richardson, Paul, Di Bacco, Alessandra

Volltext

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Prote... von Kumar, Shaji K., Cornell, Robert F., Landgren, Ola, Ailawadhi, Sikander, Higgins, Jack P, Willert, Erin K, Waltzman, Roger, Lin, Jianchang, Zhang, Yuhong, Lublinsky, Anya R, Dash, Ajeeta B, Hanley, Michael, Manoharan, Divya, Leichter, Morgan, Ottinger, Sean, Labotka, Richard J, Newcomb, John, Vorog, Alexander

Volltext

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in... von Dimopoulos, Meletios A, Gay, Francesca, Schjesvold, Fredrik H., Beksac, Meral, Hajek, Roman, Weisel, Katja, Goldschmidt, Hartmut, Maisnar, Vladimir, Moreau, Philippe, Min, Chang-Ki, Pluta, Agnieszka, Chng, Wee Joo, Kaiser, Martin, Zweegman, Sonja, Mateos, Maria-Victoria, Spencer, Andrew, Iida, Shinsuke, Morgan, Gareth, Teng, Zhaoyang, Suryanarayan, Kaveri, Skacel, Tomas, Dash, Ajeeta B, Labotka, Richard, Rajkumar, S. Vincent

Volltext

Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myel... von Swords, Ronan T, Coutre, Steven, Maris, Michael B., Zeidner, Joshua F., Foran, James M., Cruz, Jose C., Erba, Harry P., Berdeja, Jesus G., Tam, Wayne, Vardhanabhuti, Saran, Dobler, Iwona, Faessel, Hélène M., Dash, Ajeeta B., Sedarati, Farhad, Dezube, Bruce J., Savona, Michael R.

Volltext

Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for... von Swords, Ronan T, Savona, Michael R, Maris, Michael B, Erba, Harry P, Berdeja, Jesus G., Foran, James M., Hua, Zhaowei, Faessel, Hélène M, Dash, Ajeeta B, Sedarati, Farhad, Dezube, Bruce J, Medeiros, Bruno C

Volltext

The EVES motif mediates both intermolecular and intramolecular regulation of c-Myb von Dash, A B, Orrico, F C, Ness, S A

Volltext